The United States Patent and Trademark Office (USPTO) has granted patent US12583927B2 to Minerva Biotechnologies Corporation. This patent covers "Anti-variable MUC1* antibodies and uses thereof," specifically an antibody or fragment that binds to the PSMGFR peptide (SEQ ID NO:2) or a fragment thereof. The patent is intended for the diagnosis, treatment, or prevention of cancers.

This grant represents a new intellectual property right for Minerva Biotechnologies Corporation. While patents do not impose direct regulatory obligations on other entities, they can influence market exclusivity and the development of competing therapies. Companies operating in the oncology and antibody development space, particularly those working with MUC1 targets, should be aware of this granted patent as it may impact their freedom to operate or inform their research and development strategies.